1887

Abstract

SUMMARY

Studies were performed to compare the therapeutic effectiveness of three antiviral drugs (ARA-A, ARA-C and IDU) on the course of fatal disseminated vaccinia virus infection in immunosuppressed mice. Treatment with ARA-A begun as late as 7 days after virus infection was significantly effective in preventing death; no antiviral effect of the other two drugs was demonstrated.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-36-2-329
1977-08-01
2022-12-08
Loading full text...

Full text loading...

/deliver/fulltext/jgv/36/2/JV0360020329.html?itemId=/content/journal/jgv/10.1099/0022-1317-36-2-329&mimeType=html&fmt=ahah

References

  1. Dixon O. J., Sidwell R. W., Miller F. A., Sloan B. J. 1968; Antiviral activity of 9-β-d arabinofurano-syladenine. V. Activity against intracerebral vaccinia virus infections in mice. Antimicrobial Agents and Chemotherapy 1968:172–179
    [Google Scholar]
  2. Fulginiti V. A., Kempe C. H., Hathaway W. F., Pearlman D. S., Siever O. F. Jun, Eller J. J., Joyner J. J. Sen, Robinson A. 1968; Progressive vaccinia in immunologically deficient individuals. In Immunologic Deficiency Diseases in Man. Birth Defects Original Article Series vol IV pp 139–151 Edited by Bergsma D., Good R. A. New York: National Foundation;
    [Google Scholar]
  3. Levey R. H. 1970; Influences of antilymphocyte serum on cell-mediated and antibody-mediated responses. Federation Proceedings 29:156
    [Google Scholar]
  4. Levey F. H., Medawar P. B. 1966; Nature and mode of action of antilymphocytic antiserum. Proceedings of the National Academy of Sciences of the United States of America 56:1130–1137
    [Google Scholar]
  5. Levine A. S., Schimpff S. C., Graw R. G. Jun, Young R. C. 1974; Hematologic malignancies and other marrow failure states: progress in the management of complicating infections. Seminars in Hematology 11:141–202
    [Google Scholar]
  6. Montgomerie J. Z., Becroft D. M. O., Croxson M. C., Doak P. B., North J. D. K. 1969; HerpeS-simpleX-virus infection after renal transplantation. Lancet ii:867–871
    [Google Scholar]
  7. Sloan B. J., Miller F. A., Ehrlich J., Mclean I. W., Machamer H. E. 1968; Antiviral activity of 9-B-D arabinofuranosyladenine. IV. Activity against intracerebral herpes simplex virus infections in mice. Antimicrobial Agents and Chemotherapy 1968:161–171
    [Google Scholar]
  8. Stevens D. A., Jordan G. W., Waddell T. F., Merigan T. C. 1973; Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. New England Journal of Medicine 289:873–878
    [Google Scholar]
  9. St Geme J. W. Jun, Prince J. T., Burke B. A., Good R. A., Krivit W. 1965; Impaired cellular resistance to herpes-simplex-virus in Wiskott-Aldrich syndrome. New England Journal of Medicine 273:229–234
    [Google Scholar]
  10. Whitley R. J., Ch’len L. T., Dolin R., Galasso G. J., Alford C. A. Jun The Collaborative Study Group 1976; Adenine arabinoside therapy of herpes zoster in the immunosuppressed. New England Journal of Medicine 294:1193–1199
    [Google Scholar]
  11. Worthington M. 1973; Mechanism of recovery from systemic infection with vaccinia virus. III. Effects of antithymocyte serum. Journal of Infectious Diseases 127:518–524
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-36-2-329
Loading
/content/journal/jgv/10.1099/0022-1317-36-2-329
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error